BridgeBio to Showcase ATTRibute-CM Study Results at ESC Congress 2025
ByAinvest
Thursday, Aug 28, 2025 5:33 am ET1min read
BBIO--
The presentations will include a rapid oral presentation on the drug's impact on reducing cardiovascular mortality from the ATTRibute-CM study at Month 42, as well as two ePosters detailing its effectiveness at Month 30 in improving NT-proBNP levels and beneficial effects on ATTR stage in patients with ATTR-CM [1]. The key presenters include experts from Stanford University, UChicago Medicine, and University College London [1].
Acoramidis is a transthyretin stabilizer aimed at reducing cardiovascular death and hospitalizations in adults with ATTR-CM. The company has shared that common adverse reactions include diarrhea and upper abdominal pain, primarily mild in nature [1].
The participation at the European Society of Cardiology Congress enhances visibility and credibility within the medical community, potentially attracting interest from healthcare professionals and investors. New data from the study may provide further validation of Acoramidis's efficacy, supporting its use and possibly leading to increased adoption among physicians treating ATTR-CM patients [1].
References:
[1] https://www.quiverquant.com/news/BridgeBio+Pharma+to+Present+New+Data+on+Acoramidis+at+ESC+Congress+2025
BridgeBio Pharma will present additional data from its ATTRibute-CM study at ESC Congress 2025. The presentations will highlight Month 42 cardiovascular mortality results and Month 30 improvements in NT-proBNP. Key presenters include experts from Stanford University, UChicago Medicine, and University College London. The study focuses on assessing the efficacy of acoramidis in treating cardiomyopathy in wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM).
BridgeBio Pharma, Inc. (Nasdaq: BBIO) has announced that it will present new data on its drug, Acoramidis, during the European Society of Cardiology (ESC) Congress 2025 in Madrid from August 29 to September 1. The presentations will highlight the drug's impact on reducing cardiovascular mortality and improving NT-proBNP levels in patients with transthyretin-mediated amyloidosis (ATTR-CM) [1].The presentations will include a rapid oral presentation on the drug's impact on reducing cardiovascular mortality from the ATTRibute-CM study at Month 42, as well as two ePosters detailing its effectiveness at Month 30 in improving NT-proBNP levels and beneficial effects on ATTR stage in patients with ATTR-CM [1]. The key presenters include experts from Stanford University, UChicago Medicine, and University College London [1].
Acoramidis is a transthyretin stabilizer aimed at reducing cardiovascular death and hospitalizations in adults with ATTR-CM. The company has shared that common adverse reactions include diarrhea and upper abdominal pain, primarily mild in nature [1].
The participation at the European Society of Cardiology Congress enhances visibility and credibility within the medical community, potentially attracting interest from healthcare professionals and investors. New data from the study may provide further validation of Acoramidis's efficacy, supporting its use and possibly leading to increased adoption among physicians treating ATTR-CM patients [1].
References:
[1] https://www.quiverquant.com/news/BridgeBio+Pharma+to+Present+New+Data+on+Acoramidis+at+ESC+Congress+2025
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet